Alvotech (NASDAQ:ALVO) Sees Unusually-High Trading Volume – Here’s Why

Alvotech (NASDAQ:ALVO) saw strong trading volume on Friday . Approximately 1,260,668 shares traded hands during trading, an increase of 96% from the previous session’s volume of 641,961 shares.The stock last traded at $4.48 and had previously closed at $4.27.

Analyst Ratings Changes

ALVO has been the topic of a number of analyst reports. Evercore began coverage on shares of Alvotech in a report on Friday, August 14th. They set an “outperform” rating on the stock. Weiss Ratings downgraded shares of Alvotech from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Finally, Wall Street Zen lowered shares of Alvotech from a “hold” rating to a “sell” rating in a research report on Saturday, May 23rd. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $7.60.

Alvotech Trading Up 4.9%

The stock has a market cap of $1.35 billion, a PE ratio of -7.34 and a beta of 0.18. The firm has a fifty day simple moving average of $3.66 and a two-hundred day simple moving average of $3.74.

Institutional Investors Weigh In On Alvotech

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Alvotech by 2.7% in the third quarter. Vanguard Group Inc. now owns 4,348,151 shares of the company’s stock valued at $35,481,000 after purchasing an additional 114,255 shares in the last quarter. Millennium Management LLC grew its stake in Alvotech by 1,707.7% in the 4th quarter. Millennium Management LLC now owns 357,176 shares of the company’s stock worth $1,832,000 after buying an additional 337,417 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Alvotech by 88.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 259,536 shares of the company’s stock worth $1,331,000 after buying an additional 122,089 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Alvotech by 10.7% in the 4th quarter. Geode Capital Management LLC now owns 254,921 shares of the company’s stock worth $1,308,000 after buying an additional 24,667 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC bought a new position in shares of Alvotech in the 2nd quarter worth $1,782,000.

Alvotech Company Profile

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).